Medical Access and Reimbursement in Ireland

Psilocin is Schedule 1, and fungi containing psilocin or an ester of psilocin have been expressly controlled since 2006. Lawful activity is tightly restricted, with Ireland-linked psilocybin work currently research-led rather than routine care. # # #

No Irish authorised MDMA medicine or reimbursement pathway was identified. University materials reference sponsored PTSD work, but that remains investigational rather than routine care. # #

Spravato is EMA-authorised and listed in Irish medicines information. NCPE states that HSE approved reimbursement after confidential price negotiations in January 2022, indicating a real but specialist access route. # # #

Ketamine is Schedule 3, not Schedule 1, and can circulate as a controlled medicinal product. Public Irish depression activity is most visible through ketamine research, including KARMA-Dep 2, rather than a standard reimbursement pathway for off-label depression care. # #

DMT is listed in Schedule 1. No Irish authorised treatment or reimbursement route was identified outside licensed research. #

The safest public label is investigational or controlled-access only. GH001 is connected to an Irish-headquartered sponsor and published Phase IIb data, but the exact schedule mapping for 5-MeO-DMT should be manually checked before stronger legal wording is used. # #

The reviewed Irish materials did not establish an authorised ibogaine treatment or reimbursement route. Do not repeat blanket Schedule 1 wording unless the current consolidated statutory basis is manually confirmed. #

DMT is Schedule 1 and no official Irish ceremonial, medical or reimbursement pathway for ayahuasca was identified in reviewed sources. #

Mescaline is listed in Schedule 1. No Irish authorised treatment or reimbursement route was identified outside licensed research. #

Ireland's Schedule 1 framework includes many phenethylamine derivatives, but the exact mapping for each 2C-family compound should be checked before publication. No authorised treatment or reimbursement route was identified. #